glp 1 binge eating GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders Tips for prescribing GLP-1s in
Description
Semaglutide is not FDA-approved for anxiety or ADHD and should not replace established psychiatric medications
Recent reports suggest that as of 2022, 12% of adults in the United States have taken a GLP-1 agonist for weight loss at some point
FDA policy and enforcement discretion around compounded GLP-1s has shifted as national supply conditions change
Most discussions of the previously presented robust data analyses have focused on the hypothalamic-pituitary-adrenal axis and neurotrophic factors
However, the structure and frequency of scheduled monitoring may vary depending on the selected plan
